This research develops methods to insert radioactive carbon isotopes into drug molecules, allowing scientists to track how medicines move, transform, and are eliminated in the body. By using catalysts to precisely label drugs, researchers can better understand drug behaviour and accelerate the development of safer, more effective medicines.

This research addresses antibiotic resistance by developing new compounds effective against Pseudomonas aeruginosa. Using engineered Streptomyces albus, it produces uridyl peptide antibiotics with a triple-target mechanism that reduces resistance risk. The work focuses on purification and chemical optimization to create more effective, clinically viable antibiotics for future infections.